Teewinot Secures First U.S. Patent
News Jul 26, 2016
Teewinot Life Sciences Corporation has announced that it was granted the first U.S. Patent covering an apparatus for biosynthetic production of the cannabinoids THCA, CBDA and CBCA. U.S. Patent No. 9,394,510 ("the '510 patent") is scheduled to grant and is owned by Full Spectrum Laboratories, Ltd., Teewinot's wholly owned Irish subsidiary. The '510 patent claims an apparatus for a biosynthetic process of manufacturing the cannabinoids THCA, CBDA and CBCA using THCA synthase and CBDA synthase.
The apparatus facilitates the manufacture of authentic cannabinoids that are purer in form and more cost effectively produced than what is currently available in the marketplace. Teewinot's executive vice president and co-inventor of the '510 patent, Dr. Richard Peet, stated that "Teewinot has a rapidly expanding patent portfolio covering processes for the manufacture of cannabinoids, cannabinoid prodrugs and cannabinoid analogs as well as novel cannabinoids and treatment therapies."
Jeffrey M. Korentur, Teewinot's chief executive officer stated, "We are proud to add to the technological foundation that will allow this new class of medicines reach their full potential. Our processes, equipment, and expertise will, for the first time, allow for the inexpensive and rapid production of pure cannabinoids and cannabinoid-related compounds for the benefit of patient populations around the world."
With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is ready to manufacturer cannabinoids, cannabinoid prodrugs, and cannabinoid analogs worldwide.